Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$90.17 USD
-0.73 (-0.80%)
Updated Jun 24, 2024 04:00 PM ET
After-Market: $90.15 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$90.17 USD
-0.73 (-0.80%)
Updated Jun 24, 2024 04:00 PM ET
After-Market: $90.15 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum D VGM
Zacks News
CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut
by Zacks Equity Research
CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.
Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.
AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.
IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.
Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.
Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.
Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.
ALC or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALC vs. EW: Which Stock Is the Better Value Option?
DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance
by Zacks Equity Research
Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.